IQVIA Holdings Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ari Bousbib
- Full Time Employees
- 89,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2400 Ellis Road Durham NC United States of America 27703
- IPO Date
- May 9, 2013
- CIK
- 0001478242
- Website
- iqvia.com
- Similar Companies
- Business
- IQVIA Holdings Inc operates as a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries. The company offers a comprehensive portfolio including clinical trial services; commercial insights; healthcare intelligence; real-world evidence generation; and advanced data analytics powered by IQVIA Connected Intelligence™, Healthcare-grade AI™, and big data resources. Its technology solutions encompass software platforms for orchestrated customer engagement, data management, and commercial orchestration, supported by partnerships with leading technology providers such as NVIDIA and Veeva Systems. IQVIA's service offerings span drug development, regulatory consulting, market access, and patient centricity solutions, targeting pharmaceutical, biotechnology, and medical device companies worldwide. Headquartered in Durham, North Carolina, and founded through the 2016 merger of Quintiles and IMS Health, IQVIA operates in more than 100 countries with approximately 88,000 employees. Recent company developments include a strategic partnership with NVIDIA to integrate generative and agentic AI within clinical research workflows, accelerating innovation and efficiency in drug development. IQVIA also expanded a clinical and commercial collaboration with Veeva Technologies to enhance interoperability and deliver streamlined solutions for customers in clinical development and commercialization. In 2024 and 2025, IQVIA advanced its healthcare data analytics capabilities through acquisitions of healthcare technology firms, reinforcing its technology portfolio and enabling broader service offerings. Additionally, the company continues to support pharmaceutical product launches globally, tracking and analyzing launch excellence to optimize commercial success across multiple therapeutic areas. IQVIA's ongoing investments in AI and integrated technology ecosystems position it at the forefront of healthcare intelligence and life sciences services innovation.
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
Veeva vs. IQVIA: Which Life Sciences Tech Stock Holds More Promise?
Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
IQVIA: The Market May Be Missing The AI & Data Story
Artisan Select Equity Fund Q1 2026 Portfolio Update
The Broyhill Q1 2026 Portfolio Strategy And Positioning
IQVIA Holdings Inc. (IQV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
IQVIA Q1 Earnings Call Highlights
Here's What Key Metrics Tell Us About IQVIA (IQV) Q1 Earnings
Artisan Value Fund Q1 2026 Portfolio Activity
IQVIA Holdings Inc. (IQV) Q1 2026 Earnings Call Transcript
IQV Q1 Earnings Beat on Commercial Solutions Strength
IQVIA Holdings (IQV) Q1 Earnings and Revenues Beat Estimates
IQVIA Set to Report Q1 Earnings: Here's What You Should Know
Veeva Systems Just Joined the S&P 500. 3 Reasons to Buy It and 1 Not To.
D.A. Davidson & CO. Boosts Stock Position in IQVIA Holdings Inc. $IQV
Concurrent Investment Advisors LLC Buys 3,161 Shares of IQVIA Holdings Inc. $IQV
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?